Tislelizumab
beigene,novartis
at #wcgic2022, dr harry yoon presents interim analysis data for the phase iii rationale 306 trial comparing first-line treatment with a pd-1 inhibitor + chemo to chemo alone in patients with advanced or metastatic #escc. abstract lba-1 
Committed to providing medical & scientific disease education information to healthcare professionals. See our community guidelines: https://t.co/pj8hG1sQAu